MH

Analyst Note: McGraw Hill, Inc. (MH)

Date: 2026-06-20 Current Price: $9.68

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 8.2% (Extreme)

Analysis:

Per StoryStocks protocol, a FORMING coil is a PARTIAL signal. It is not invalidated, but it is not actionable on its own. The current ATR of 8.2% is classified as Extreme, which historically correlates with the highest rate of severe losers in the dataset. This extreme volatility suggests that while the structure is intact, the market is currently in a high-noise environment where a false breakout or a sharp retest of support is statistically probable. The setup requires a confirmed close above the breakout level to transition to a CONFIRMED-ACTIVE state.

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Thesis: None

There is no named secular thesis attached to MH as of this date. The investment case is strictly TACTICAL, driven by the quality of the technical setup and the immediate fundamental backdrop rather than a broad macroeconomic tailwind. The conviction must be derived entirely from the structural readiness of the chart and the strength of the business fundamentals reported in the recent earnings cycle. No external macro drivers (e.g., specific government spending bills, AI regulatory shifts) are currently cited as primary catalysts in the evidence base.

3. Business Overview

Company: McGraw Hill, Inc. Industry: Communication Services (Education Solutions) Business Model: Provider of end-to-end digital and print learning solutions across K-12, Higher Education, and Professional Learning.

Operational Details (as of June 2026):

• Market Position: The company is a dominant player in the U.S. education market. It serves approximately 91% of U.S. public K-12 districts and 81% of U.S. higher education institutions (E16, E17).
• Revenue Scale: For the fiscal year ended March 31, 2026, the company generated $2,102.8 million in revenue, up from $2,101.3 million in FY2025 and $1,960.5 million in FY2024 (E18).
• Profitability & Cash Flow: The company has returned to profitability, reporting a net income of $35.3 million for FY2026, a significant recovery from a loss of $85.8 million in FY2025 (E18). Management expects Adjusted EBITDA to be in the range of $750 million–$790 million for the current period, ahead of IPO expectations (E1). Unlevered free cash flow is expected to reach approximately $400 million, representing a 20% year-over-year increase (E3).
• Backlog & Visibility: The remaining performance obligation (RPO) stands at $1.7 billion, with expectations for growth in the fiscal second quarter of 2027 due to K-12 seasonality (E2).
• User Base: The company reports over 100 million active licenses by students and educators (E4).
• Segment Mix: The global professional business is heavily weighted toward medical education, which represents more than 75% of revenue in that segment (E5).
• Capital Structure: Following the IPO on July 25, 2025, the company used net proceeds to repay $385.7 million of debt (E12). In September 2025, the company amended its credit agreement to reduce the applicable margin by 50 basis points, lowering interest costs (E13).
• Global Reach: Solutions are available in over 100 countries and 80 languages (E10).

4. Archetype and Conviction

Archetype: Margin Inflector / Quality Compounder The company fits the profile of a Margin Inflector transitioning into a Quality Compounder. The evidence shows a clear trajectory from losses (FY2024/2025) to profitability (FY2026) driven by the monetization of a massive installed base (100M+ licenses) and a shift to high-margin digital subscriptions. The "inflection" is evidenced by the 20% YoY growth in unlevered free cash flow and the return to positive net income.

Conviction Stack:

• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. The evidence base is robust, citing specific financial metrics, market share dominance, and clear management guidance on EBITDA and FCF.
• Structural Quality: Moderate. The setup is "Forming," meaning the technical structure is present but unconfirmed. The Extreme ATR (8.2%) is a significant negative factor, suggesting high volatility risk and a higher probability of a failed breakout compared to the historical sweet spot (4–6%).
• Rerating Potential: Moderate. The market is pricing in the recovery, but the "Extreme" volatility suggests the market is still digesting the transition from loss to profit.

Valuation Context: While specific P/E or EV/EBITDA multiples are not provided in the evidence, the company's ability to generate $400M in unlevered free cash flow on $2.1B in revenue (approx. 19% FCF margin) suggests a high-quality asset. The debt reduction ($385M repaid) and improved credit terms further support a valuation rerating, provided the technical setup confirms.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Fundamental: A miss on the $750M–$790M EBITDA guidance or a contraction in the $1.7B RPO.
• Operational: A significant decline in the 100M active license count or a failure to maintain the 91% K-12 district penetration.

What Would Strengthen:

• Technical: A confirmed breakout close above the consolidation ceiling (breakout level) with volume expansion.
• Fundamental: Confirmation of the 20% FCF growth trajectory into FY2028 as guided.
• Strategic: Successful expansion of the AI-powered diagnostic simulations into the clinical training market (addressing the 11M worker shortage).

Gaps in Evidence:

• Valuation Multiples: No explicit P/E, EV/EBITDA, or price-to-sales ratios are provided to benchmark against peers.
• Competitive Landscape: While market share is cited, there is no specific data on competitor pricing or churn rates.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 1. Return to profitability with $35.3M net income in FY2026 after losses in prior years. 2. Strong cash flow generation with $400M unlevered FCF expected (20% YoY growth). 3. Dominant market position serving 91% of US public K-12 districts and 81% of higher ed institutions. Key risks: 1. Extreme ATR of 8.2% indicates high volatility and elevated risk of false breakouts. 2. Setup is currently "Forming" with no confirmed breakout level or entry price. 3. Lack of a named secular macro thesis; purely tactical exposure. Sizing hint: Reduce position size relative to standard setups due to extreme volatility and unconfirmed technical structure. Expected path: Management expects continued EBITDA growth and FCF expansion into FY2028; technical structure requires a confirmed breakout above consolidation to validate the bullish case. Expected horizon: 3 to 6 months for technical confirmation or invalidation.